Sarepta Therapeutics, Inc. (LON:0L35)
London
· Delayed Price · Currency is GBP · Price in USD 54.32
+0.47 (0.87%)
At close: Apr 17, 2025
Sarepta Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,902 | 1,243 | 933.01 | 701.89 | 540.1 | Upgrade
|
| Revenue Growth (YoY) | 52.97% | 33.26% | 32.93% | 29.95% | 41.82% | Upgrade
|
| Cost of Revenue | 1,124 | 1,028 | 1,017 | 862.13 | 785.63 | Upgrade
|
| Gross Profit | 778.36 | 215.61 | -84.07 | -160.24 | -245.53 | Upgrade
|
| Selling, General & Admin | 557.87 | 481.87 | 451.42 | 282.66 | 317.88 | Upgrade
|
| Operating Expenses | 560.28 | 483.43 | 452.14 | 283.37 | 318.54 | Upgrade
|
| Operating Income | 218.08 | -267.82 | -536.2 | -443.61 | -564.06 | Upgrade
|
| Interest Expense | -18.39 | -22.01 | -53.25 | -63.53 | -59.95 | Upgrade
|
| Interest & Investment Income | 30.64 | 36.26 | 16.49 | 0.35 | 2.97 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.85 | 0.62 | -6.92 | -0.94 | 0.52 | Upgrade
|
| EBT Excluding Unusual Items | 227.48 | -252.96 | -579.88 | -507.72 | -620.52 | Upgrade
|
| Gain (Loss) on Sale of Investments | 41.13 | 19.39 | 8.66 | -4.33 | 4.49 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 102 | - | 102 | 108.07 | Upgrade
|
| Asset Writedown | - | - | - | - | -0.1 | Upgrade
|
| Other Unusual Items | -7.84 | -388.53 | -118.74 | -8.9 | -45 | Upgrade
|
| Pretax Income | 260.77 | -520.1 | -689.96 | -418.95 | -553.07 | Upgrade
|
| Income Tax Expense | 25.54 | 15.88 | 13.53 | -0.17 | 1.06 | Upgrade
|
| Net Income | 235.24 | -535.98 | -703.49 | -418.78 | -554.13 | Upgrade
|
| Net Income to Common | 235.24 | -535.98 | -703.49 | -418.78 | -554.13 | Upgrade
|
| Shares Outstanding (Basic) | 95 | 92 | 88 | 81 | 78 | Upgrade
|
| Shares Outstanding (Diluted) | 108 | 92 | 88 | 81 | 78 | Upgrade
|
| Shares Change (YoY) | 16.75% | 5.53% | 7.75% | 4.24% | 5.90% | Upgrade
|
| EPS (Basic) | 2.47 | -5.80 | -8.03 | -5.15 | -7.11 | Upgrade
|
| EPS (Diluted) | 2.34 | -5.80 | -8.03 | -5.15 | -7.11 | Upgrade
|
| Free Cash Flow | -342.74 | -577.1 | -356.17 | -481.66 | 25.26 | Upgrade
|
| Free Cash Flow Per Share | -3.18 | -6.25 | -4.07 | -5.93 | 0.32 | Upgrade
|
| Gross Margin | 40.92% | 17.34% | -9.01% | -22.83% | -45.46% | Upgrade
|
| Operating Margin | 11.47% | -21.54% | -57.47% | -63.20% | -104.44% | Upgrade
|
| Profit Margin | 12.37% | -43.11% | -75.40% | -59.66% | -102.60% | Upgrade
|
| Free Cash Flow Margin | -18.02% | -46.41% | -38.17% | -68.62% | 4.68% | Upgrade
|
| EBITDA | 255.81 | -223.43 | -494.34 | -405.59 | -537.6 | Upgrade
|
| EBITDA Margin | 13.45% | -17.97% | -52.98% | -57.79% | -99.54% | Upgrade
|
| D&A For EBITDA | 37.72 | 44.4 | 41.86 | 38.02 | 26.46 | Upgrade
|
| EBIT | 218.08 | -267.82 | -536.2 | -443.61 | -564.06 | Upgrade
|
| EBIT Margin | 11.47% | -21.54% | -57.47% | -63.20% | -104.44% | Upgrade
|
| Effective Tax Rate | 9.79% | - | - | - | - | Upgrade
|
| Revenue as Reported | 1,902 | 1,243 | 933.01 | 701.89 | 540.1 | Upgrade
|
| Advertising Expenses | 32 | 28.6 | 14.6 | 7.7 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.